Aberrant expression of LMO2, following activation by retroviral insertion, has also led to a T-ALL-like leukaemia arising in four of the children treated in X chromosome-linked severe combined immuno-deficiency syndrome (X-SCID) gene therapy trials [9,10,38]. This evidence concerns the gene LMO2 and leukemia.